Bhaskar Chaudhuri. Frazier Healthcare Partners

Fra­zier Health­care Part­ner­s' der­ma­tol­ogy up­start at­tracts a mar­quee syn­di­cate, $94M+ for 'in-be­tween' top­i­cal drug

For the past three years Fra­zier Health­care Part­ners’ Bhaskar Chaud­huri has been care­ful­ly and qui­et­ly groom­ing Ar­cutis Ther­a­peu­tics, a new der­ma­tol­ogy play he co-found­ed to de­liv­er top­i­cal for­mu­la­tions of well-known drugs. Now that the biotech is poised to en­ter Phase III, he’s be­ing joined by a mar­quee syn­di­cate for its $94.5 mil­lion Se­ries C.

HBM Health­care In­vest­ments, Vi­vo Cap­i­tal, Black­Rock, Omega Funds, Piv­otal BioVen­tures, and Gold­man Sachs jumped on board, join­ing Bain Cap­i­tal Life Sci­ences, Or­biMed and RA Cap­i­tal Man­age­ment in back­ing Ar­cutis’ lead top­i­cal cream for plaque pso­ri­a­sis.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.